Physician profile
Sapan Bindal
NPI 1447645049
$1,845.51
in general payments reported to CMS, 2019-2025
26 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.55 · 2020: $14.42 · 2021: $118 · 2022: $395 · 2023: $410 · 2024: $556 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206 · Education: $19.62 · Entertainment: $19.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.84 |
| Education | $19.62 |
| Entertainment | $19.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $609.99 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $263.15 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $174.27 | 2022-2025 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $147.94 | 2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $103.88 | 2022-2024 | |
| Sanofi Pasteur INC. | $66.63 | 2023-2024 | |
| Glaxosmithkline, LLC. | $49.53 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.36 | 2019-2022 | |
| Pfizer INC. | $42.22 | 2023-2025 | |
| Amgen INC. | $37.39 | 2019-2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $35.88 | 2021-2022 | |
| Medtronic, INC. | $31.76 | 2021-2022 | |
| Eisai INC. | $21.15 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.37 | 2021 | |
| Optos, INC. | $19.11 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $18.38 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $17.87 | 2022 | |
| Abbott Laboratories | $17.75 | 2025 | Eterna |
| Abbvie INC. | $17.45 | 2021 | |
| Seqirus USA INC | $17.19 | 2022 | |
| Biotronik Nro, INC. | $16.00 | 2025 | Prospera |
| Sumitomo Pharma America, INC. | $15.94 | 2025 | Myfembree |
| Currax Pharmaceuticals LLC | $15.45 | 2022 | |
| Allergan, INC. | $14.42 | 2020 | |
| Vistapharm, INC. | $12.87 | 2021 | |
| Genentech USA, INC. | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sapan Bindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.